While Biogen’s share rose a stellar 40% yesterday, the development helped some other pharmaceutical stocks with Alzheimer’s treatments in the pipeline, including Roche, Eli Lilly, and Prothena. The company’s diagnostics business, which led the revenue growth since the beginning of the pandemic due to high demand for Covid-19 testing, is expected to see a decline in sales in the near term. A sell-off in broader markets due to higher inflation and rising interest rates slowing the economic growth isn’t helping Roche stock either.